Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
1.63
Dollar change
+0.01
Percentage change
0.62
%
Index- P/E- EPS (ttm)-3.65 Insider Own8.51% Shs Outstand16.79M Perf Week3.82%
Market Cap27.37M Forward P/E- EPS next Y-1.81 Insider Trans-0.24% Shs Float15.36M Perf Month-10.93%
Income-52.53M PEG- EPS next Q-0.59 Inst Own18.69% Short Float1.90% Perf Quarter-4.68%
Sales0.00M P/S- EPS this Y56.26% Inst Trans116.21% Short Ratio2.80 Perf Half Y-31.51%
Book/sh2.48 P/B0.66 EPS next Y34.42% ROA-51.08% Short Interest0.29M Perf Year-16.41%
Cash/sh2.74 P/C0.60 EPS next 5Y- ROE-91.54% 52W Range1.46 - 3.82 Perf YTD-15.54%
Dividend Est.- P/FCF- EPS past 5Y9.63% ROI-86.63% 52W High-57.33% Beta0.87
Dividend TTM- Quick Ratio5.74 Sales past 5Y-23.77% Gross Margin-697.46% 52W Low11.60% ATR (14)0.09
Dividend Ex-Date- Current Ratio5.74 EPS Y/Y TTM53.62% Oper. Margin0.00% RSI (14)49.77 Volatility3.73% 6.78%
Employees32 Debt/Eq0.67 Sales Y/Y TTM-100.00% Profit Margin- Recom1.00 Target Price6.00
Option/ShortYes / Yes LT Debt/Eq0.67 EPS Q/Q23.05% Payout- Rel Volume0.32 Prev Close1.62
Sales Surprise- EPS Surprise-22.31% Sales Q/Q- EarningsNov 13 AMC Avg Volume104.23K Price1.63
SMA201.75% SMA50-4.46% SMA200-24.76% Trades Volume34,617 Change0.62%
Date Action Analyst Rating Change Price Target Change
Nov-16-23Upgrade Wedbush Neutral → Outperform $2 → $4
Jan-04-22Upgrade ROTH Capital Neutral → Buy
Nov-10-21Upgrade Mizuho Neutral → Buy $5 → $7
Jun-28-21Upgrade Citigroup Sell → Buy $6
Jun-07-21Initiated H.C. Wainwright Buy $12
Feb-16-21Downgrade Citigroup Neutral → Sell $5 → $6
Aug-18-20Downgrade Morgan Stanley Overweight → Equal-Weight $5
Aug-18-20Downgrade Mizuho Buy → Neutral $33 → $4
Aug-18-20Downgrade Citigroup Buy → Neutral $31 → $5
Aug-17-20Downgrade ROTH Capital Buy → Neutral
Feb-06-24 08:00AM
Dec-29-23 04:37PM
Dec-12-23 08:00AM
Nov-13-23 04:05PM
Nov-10-23 08:00AM
05:14PM Loading…
Oct-17-23 05:14PM
Oct-03-23 09:36PM
Sep-27-23 07:00AM
Sep-16-23 01:02AM
Aug-15-23 04:51PM
Aug-08-23 04:05PM
Jun-21-23 07:00AM
May-09-23 04:05PM
Apr-24-23 01:34PM
07:00AM
06:00PM Loading…
Apr-23-23 06:00PM
Mar-28-23 03:25PM
Mar-27-23 01:28PM
07:30AM
Mar-15-23 04:05PM
Feb-28-23 04:05PM
Feb-15-23 08:00AM
Feb-09-23 08:00AM
Jan-18-23 08:00AM
Jan-10-23 10:36AM
Nov-08-22 04:10PM
Nov-01-22 07:00AM
Oct-31-22 06:11PM
Oct-19-22 08:30AM
Oct-11-22 08:00AM
12:00PM Loading…
Oct-10-22 12:00PM
Oct-06-22 08:00AM
Sep-19-22 08:00AM
07:00AM
Aug-31-22 08:00AM
Aug-30-22 09:55AM
Aug-17-22 11:04PM
Aug-16-22 04:01PM
Aug-12-22 09:18AM
07:05AM
07:00AM
Aug-11-22 05:45PM
Jul-12-22 04:00PM
Jun-29-22 08:00AM
May-26-22 08:00AM
May-25-22 08:00AM
May-10-22 04:00PM
May-05-22 08:00AM
Apr-21-22 08:00AM
Apr-19-22 08:00AM
Apr-12-22 08:00AM
Mar-17-22 12:51PM
Mar-15-22 08:00AM
Mar-01-22 08:00AM
Feb-14-22 08:00AM
Feb-03-22 06:00PM
04:01PM
Feb-02-22 08:00AM
Jan-25-22 05:38PM
Jan-04-22 08:00AM
Dec-22-21 08:00AM
Dec-20-21 08:00AM
Nov-10-21 12:35PM
08:00AM
Nov-09-21 07:00AM
Nov-03-21 08:00AM
Oct-06-21 08:00AM
Oct-05-21 12:15PM
07:00AM
Oct-04-21 01:00AM
Sep-07-21 04:00PM
Aug-18-21 08:00AM
Aug-16-21 04:03PM
Aug-10-21 04:01PM
Jul-28-21 07:40PM
08:00AM
Jul-23-21 08:00AM
Jul-06-21 08:59AM
07:00AM
Jun-18-21 03:03PM
Jun-08-21 08:25AM
Jun-02-21 08:00AM
May-11-21 08:00AM
May-01-21 07:00AM
Apr-28-21 08:00AM
Apr-21-21 08:00AM
Mar-23-21 04:01PM
Mar-11-21 04:05PM
Mar-08-21 08:00AM
Feb-26-21 04:05PM
Feb-24-21 08:00AM
Feb-08-21 08:00AM
Feb-03-21 08:00AM
Feb-01-21 08:00AM
Jan-12-21 10:44AM
Dec-22-20 07:45AM
Dec-16-20 08:00AM
Dec-14-20 07:00AM
Dec-02-20 10:56AM
Nov-04-20 04:01PM
Unity Biotechnology, Inc. operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic programs in ophthalmologic and neurologic disorders. The company was founded by Nathaniel Eames David, Jan van Deursen, Judith Campisi, and Daohong Zhou on March 30, 2009 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ghosh AnirvanChief Executive OfficerFeb 02 '24Sale1.716801,16378,746Feb 05 04:05 PM
Ghosh AnirvanChief Executive OfficerJan 30 '24Sale1.711,1832,02379,426Jan 31 04:05 PM
Ghosh AnirvanChief Executive OfficerNov 02 '23Sale1.835891,07880,609Nov 03 04:05 PM
Ghosh AnirvanChief Executive OfficerOct 30 '23Sale1.901,0241,94681,198Oct 31 04:05 PM
Ghosh AnirvanChief Executive OfficerSep 14 '23Sale2.471,2463,07882,222Sep 15 04:08 PM
Ghosh AnirvanChief Executive OfficerAug 02 '23Sale2.945811,70883,468Aug 03 04:13 PM
Ghosh AnirvanChief Executive OfficerJul 31 '23Sale2.861,0202,91784,049Aug 01 04:05 PM
Ghosh AnirvanChief Executive OfficerJun 26 '23Sale3.201,1773,76685,069Jun 27 05:10 PM
Ghosh AnirvanChief Executive OfficerJun 14 '23Sale3.391,2124,10986,246Jun 15 05:58 PM
Ghosh AnirvanChief Executive OfficerMay 02 '23Sale2.175881,27687,458May 03 05:26 PM
Ghosh AnirvanChief Executive OfficerMay 01 '23Sale2.151,0202,19388May 02 04:32 PM
Ghosh AnirvanChief Executive OfficerMar 31 '23Sale1.701,9593,33089,066Apr 03 04:55 PM
Dananberg JamieChief Medical OfficerMar 31 '23Sale1.7042071462,817Apr 03 04:51 PM